 |
市場調查報告書
商品編碼
1672769
GLP-1 受體促效劑市場依藥物類別、給藥途徑、應用、通路及地區分類GLP-1 Receptor Agonist Market, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
2025 年全球 GLP-1 受體促效劑市場規模估計為 281.9 億美元，預計到 2032 年將達到 635.4 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 12.3%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 281.9億美元 |
| 效能資料 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025 年至 2032 年複合年成長率 | 12.30％ | 2032 年金額預測 | 635.4億美元 |
GLP-1受體促效劑是治療第2型糖尿病的重要抗糖尿病藥物。它們模仿內源性Glucagon-Like Peptide-1(GLP-1) 的作用，GLP-1 是一種餐後分泌的胜肽激素，可刺激胰島素分泌並以葡萄糖依賴性方式抑制升糖素分泌。透過結合並活化 GLP-1 受體，這些藥物可誘導胰島素分泌、抑制升糖素分泌、抑制食慾並促進糖尿病患者減肥。與其他治療類別相比，卓越的血糖控制和低低血糖風險使其成為一種有吸引力的選擇，從而推動了市場成長。
市場動態
全球 GLP-1 受體促效劑市場的成長是由世界範圍內糖尿病盛行率的上升以及 GLP-1 受體促效劑優異的治療效果所推動的。肥胖問題的加劇增加了罹患第 2 型糖尿病的風險，對更有效的治療方法的需求也日益增加。然而，高昂的開發成本和嚴格的監管核准可能會阻礙市場成長。具有改良配方、靈活劑量選擇、更長作用時間及多種藥物組合等特點的新產品的推出，可能帶來成長機會。開發商正在投入研發力量，開發口服製劑，以擴大臨床應用並提高患者的便利性。
研究的主要特點
本報告對全球 GLP-1 受體促效劑市場進行了詳細分析，並展示了預測期（2025-2032 年）的市場規模（以十億美元計）和年複合成長率（CAGR%），以 2024 年為基準年。
它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。
它還提供了關於市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。
本報告根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，介紹了全球 GLP-1 受體促效劑市場的主要企業。
該研究涉及的主要企業包括 Novo Nordisk A/S、Eli Lilly and Company、Sanofi 等。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
全球 GLP-1 受體促效劑市場報告針對該行業的各個相關人員，例如投資者、供應商、產品製造商、分銷商、新進業者和金融分析師。
相關人員將透過全球 GLP-1 受體促效劑市場分析中使用的各種策略矩陣更輕鬆地做出決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- 一致的機會圖 (COM)
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 限制因素
- 機會
- 影響分析
- 市場趨勢
- 監管情景
- 收購和合作場景
- 資金籌措和投資
- PEST分析
- 波特的分析
4.全球GLP-1 受體促效劑市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 市場影響
5. 2020 年至 2032 年全球 GLP-1 受體促效劑市場（依藥物類別分類）（十億美元）
- 介紹
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- albiglutide
- Semaglutide
6. 2020 年至 2032 年按給藥途徑分類的全球 GLP-1 受體促效劑市場（十億美元）
- 介紹
- 腸外
- 口服
7. 2020 年至 2032 年全球 GLP-1 受體促效劑市場（按應用分類）（十億美元）
- 介紹
- 2 型糖尿病
- 肥胖
- 肝硬化
- 非酒精性脂肪肝
- 其他
8. 2020-2032 年全球 GLP-1 受體促效劑市場按分銷管道分類（十億美元）
- 介紹
- 醫院藥房
- 零售藥局
- 網路藥局
9. 2020 年至 2032 年全球 GLP-1 受體促效劑市場（按地區分類）（十億美元）
- 介紹
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第10章 競爭格局
- 公司簡介
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis bIoTech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
第 11 章 分析師建議
- 興衰
- 一致的機會地圖
第 12 章參考文獻與調查方法
- 參考
- 調查方法
Global GLP-1 Receptor Agonist Market is estimated to be valued at USD 28.19 Bn in 2025 and is expected to reach USD 63.54 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 28.19 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.30% | 2032 Value Projection: | USD 63.54 Bn |
GLP-1 receptor agonists are an important class of anti-diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon-like peptide-1 (GLP-1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. By binding to and activating the GLP-1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.
Market Dynamics:
Global GLP-1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP-1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi-indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.
Key Features of the Study:
This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global GLP-1 receptor agonist market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market
Detailed Segmentation-
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- Parenteral
- Oral
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Cassiopea
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global GLP-1 Receptor Agonist Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global GLP-1 Receptor Agonist Market, By Drug Class, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Exenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liraglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dulaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lixisenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Albiglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Semaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global GLP-1 Receptor Agonist Market, By Route of Administration, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global GLP-1 Receptor Agonist Market, By Application, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Type 2 Diabetes Mellitus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Obesity
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver Cirrhosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-alcoholic Steatohepatitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global GLP-1 Receptor Agonist Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global GLP-1 Receptor Agonist Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Eli Lilly and Company
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
